BofA update shows where active managers are putting money
OCALA, Fla. - AIM ImmunoTech Inc. (NYSE American:AIM), currently trading at $7.20 per share with a market capitalization of $669 million, announced Tuesday the pricing of a public offering expected to raise approximately $8 million in gross proceeds before deducting placement agent fees and expenses. According to InvestingPro data, the company faces liquidity challenges with a current ratio of 0.26.
The offering consists of 2,000,000 shares of common stock (or pre-funded warrants) at $4.00 per share, along with Class E warrants and Class F warrants to purchase up to an additional 2,000,000 shares each. The Class E warrants will expire five years after issuance, while the Class F warrants have an 18-month term. Both warrant classes carry an exercise price of $4.00 per share. With negative EBITDA of $17.41 million in the last twelve months, this capital raise appears crucial for the company’s operations.
Maxim Group LLC is serving as the sole placement agent for the transaction, which is expected to close around July 30, subject to customary closing conditions.
The securities are being offered through a registration statement on Form S-1 that was declared effective by the Securities and Exchange Commission on July 28.
AIM ImmunoTech focuses on developing therapeutics for cancers, immune disorders and viral diseases, including COVID-19. The company’s lead product is Ampligen (rintatolimod), described as a first-in-class investigational drug that acts as a TLR3 agonist immuno-modulator. InvestingPro analysis reveals 15+ additional insights about the company’s financial health and market position, available to subscribers.
This article is based on information from a company press release statement.
In other recent news, AIM ImmunoTech Inc. has resumed trading on the NYSE American exchange under its original ticker symbol "AIM" and a new CUSIP number 00901B303. The company, which is involved in developing therapeutics for various health conditions, announced this development in a press release. This marks a notable update for AIM ImmunoTech as it continues its operations in the financial markets. The resumption of trading is a significant step for the company. Investors may find this development important as it could impact the company’s financial visibility and accessibility. AIM ImmunoTech’s focus on therapeutics positions it in a unique spot within the pharmaceutical industry. These recent developments are crucial for stakeholders monitoring the company’s progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.